An LLM platform lets epilepsy patients text with their EEG device
Retraining the seizure detector on patient feedback alone cut false alarms by 77–81% in a pseudoprospective simulation
Science Frontiers
Briefs on new papers and preprints across organoids, disease models, AI drug design, tumor immunology and cell therapy, autoimmunity, vaccines, antibody engineering, nucleic-acid medicines and precision oncology. Each brief gives the study design, key numbers, limitations and what it could mean for drug development, with a DOI link.
Browse by field
OrganoidsOrganoidsOrganoids and organ chips4 articles
Disease modelsDisease modelsHumanized and disease models3 articles
AI drug designAI drug designML for targets and molecules7 articles
Tumor immunology & cell therapyTumor immunologyT cells, checkpoints, CAR-T6 articles
Autoimmunity & transplantAutoimmunityTolerance and autoimmunity6 articles
Vaccines & infection immunologyVaccinesVaccines and infection immunity4 articles
Antibody engineeringAntibodiesBispecifics, ADCs, design5 articles
Nucleic acid & gene therapyNucleic acidssiRNA, mRNA, LNP, editing5 articles
Precision oncology & translationPrecision oncologyBiomarkers and resistance3 articles
All articles
43 articles, newest firstAll fields
Field
FJ-0125 blocks IL-18 and IL-4Rα and outperforms dupilumab in a dermatitis mouse model
Fusing IL-18BP to a humanized anti-IL-4Rα antibody suppressed type 1, 2 and 3 inflammation more broadly than dupilumab or IL-18BP-Fc
CD19 CAR-engineered Tregs promote durable tolerance in lupus models
A CD19 CAR plus constitutive FOXP3 turns CD4 T cells into regulatory cells that both deplete B cells and suppress autoimmunity
Restoring IL-15 signalling boosts innate immunity in brain metastasis
The brain starves innate lymphoid cells of IL-15; restoring it locally lets them control metastasis without T cells
TEM1657 suppresses NFKBIZ and eases psoriasis-like inflammation in mice
A plant-derived small molecule tunes mitochondrial dynamics to switch off the NFKBIZ program that drives psoriatic inflammation
MedGemma brings open medical vision-language models to Gemma 3
One open-weight model family, medically tuned from Gemma 3, spanning medical images and text
Shotgun engineering rebuilds amino acid synthesis in CHO and Jurkat cells
Barcoded constructs delivered at high multiplicity turn each cell into its own pathway experiment
In vivo BCMA CAR-T phase 1: 15 months of follow-up, one ongoing sCR
Green CAR-T cells attacking a red myeloma cell at right
A pIgR bispecific raises cynomolgus BAL exposure 5.5-fold
A bispecific crossing airway epithelial cells and released at the airway surface
Synthetic TCR library: on average only 56% of VDJdb TCRs reproduce their annotated reactivity
Green peptide-MHC complexes binding synthetic TCRs, with one non-reproducing case marked in red
Targeting ZMYND8 increases effector-like exhausted T cells in mice and enhances immunotherapy responses
Green immune cells attacking red tumour cells
TSC2 loss produces astrocyte reactivity in organoids at all 3 time points
Astrocytes in a brain organoid cross-section, with reactive cells in red
Human cortical organoids in apallial mice: grafts make up 91.9% of cortical volume
The green area in a brain cross-section is the transplanted human cortical organoid
Human DPP9 loss causes HSPC depletion through CARD8 pyroptosis
A normal haematopoietic stem cell at left and a pyroptotic, ruptured cell at right
A single inhaled dose of ARO-RAGE lowered BALF sRAGE by 90.2%
Alveoli and droplets at left, with the siRNA cleaving messenger RNA at right
Charge-switchable LNPs did not raise IL-6 and other inflammatory cytokines in LPS-pretreated mice
Lipid particles and a macrophage, with sparse red inflammatory cytokines at right
Rentosertib phase 2a: 21/54 aging-clock comparisons significant
A cell cluster with red-marked molecules, showing proteomic aging-related changes
Four humanized DMD lines: deletions of exon 44, 45, 51 or 53
The red exon in the row is the one being skipped, with muscle fibres at right
Anti-CD19 CAR-T in refractory MG: 3 patients in treatment-free remission for at least 19 months
The neuromuscular junction at left, CAR-T cells clearing red B cells at right
Cortical organoids at 5 years: methylation clocks track time with r=0.88–0.90
Organoids growing progressively larger, with red dots on the DNA strand below marking methylation sites
511 AI antibodies benchmarked: only 9.8–13.8% beat the control in Challenge 2
Many antibodies pointing at a green antigen, with the best binder in red
Triple therapy at 72 hours: 8 infant macaques aviraemic for 6 months off treatment
Virus particles and three drug chains, with red marking suppressed virus
A 256-model tumour organoid biobank, with 162 genome-wide CRISPR screens completed
Clustered tumour organoids, with red dots marking dependency genes hit in CRISPR screens
HCMI resource: 97.8% of 421 matched pairs retain at least two classes of DNA features
Tumour and model tissue masses linked by a DNA strand, with red dots marking retained DNA features
A 156-member bispecific screen selects a low-affinity SIRPα×CD38
A macrophage phagocytosing the tumour cell at right via a red bispecific
RAG-17 phase 1 in 6 patients: cerebrospinal fluid SOD1 down 69% and 56%
A red strand inside a motor neuron cell body representing the silenced messenger RNA
A trispecific IL-2R antibody reaches an EC50 of 0.015 nM with Treg bias
A green trispecific antibody binding a dark green regulatory T cell, with the rest quiescent
12 diet models: 4/6 obesogenic diets associated with anti-PD-1 response
Intestinal villi and microbiota at left, T cells and a red tumour at right
44% of rhesus macaques developed serum bnAb activity after the complete sequential HIV vaccine regimen
Three generations of B cells maturing step by step, with antibodies binding the viral spike at right
NISE zero-shot design of drug-binding proteins: APEX affinity of 80 pM
A green designed protein enclosing a red small-molecule drug
Germinal validation: 43–101 designs across 4 antibody targets
Four green targets each bound by a designed antibody, with one epitope in red
251 samples across 11 ASD mouse models: a transient radial glia delay
Red marks the delay among radial glial fibres, with multiple models in the right column
A single dose of PE-LNP achieved 49% precise editing across the mouse liver
A lipid particle carrying red editing components into a hepatocyte
Observational study: mRNA-1010 recipients had larger increases in memory B cells
A cross-section of a lymph node germinal centre, with memory B cells at right
A 160-member bispecific library: surface properties predictable from parents, ρ up to 0.95
Two parental antibodies combining into a bispecific, with red dots marking surface properties
GPR15 guides regulatory CD8 T cells to the colon, with a 42% reduction in sporadic UC
Green regulatory T cells homing to the intestinal epithelium, with red dots marking homing receptors
Two highly sensitized patients transplanted after dual-target CAR-T
Five green CAR-T cells and one red target cell, with a kidney at right
SEZ6-targeting ADC phase 1: a 52% response rate in relapsed/refractory SCLC
An antibody binds a cell surface receptor and carries a red drug into the cell
Transient confinement culture gives small intestinal organoids a 100% engraftment rate with early transplantation
Ring-shaped small intestinal organoids in a dish, with one on the right engrafted into the intestinal wall
A fungal glycan adjuvant extends COVID-19 mRNA vaccine protection to day 500
Lipid particles with mannan chains, a dendritic cell and a B cell producing antibodies
Intratumoural anti-CTLA4 + anti-PD1: 24.3% grade 3–4 toxicity at 6 months
Intratumoural antibody injection, antibody delivered through a vessel, T cells infiltrating the tumour
Agent-designed nanobodies: 46 confirmed, best KD 0.66 nM
An AI network at left, nanobodies in the middle, binding a red target at right
Hashimoto's thyroiditis: 135 distinct TNFRSF14 mutations in a single donor
Thyroid follicles at left, B cell clones at right, with red dots marking mutations
No articles in this field yet.